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Non-Hodgkin’s lymphoma (NHL) consists of a group of neoplasias involving mainly B cells and 
represents 90% of all lymphomas. The current available therapy is based on chemotherapy associated 
with the monoclonal antibody rituximab (Mab Thera®), which targets the CD20 protein, present in over 
80% of NHL mature B cells. Recent clinical reports show a preference for combining the benefits of 
immunotherapy and adjuvant chemotherapy, thus generating safe and effective alternative treatments. The 
current review aimed at evaluating various aspects related to the use of rituximab for NHL, highlighting 
the possible inhibitory mechanisms of cell proliferation, the achieved clinical results, and the expected 
clinical and economic outcomes of treatments. The results from clinical tests indicate the need for a better 
understanding of the critical mechanisms of action of this antibody, which may maximize its therapeutic 
efficacy. This therapy not only represents a viable option to treat most types of NHLs, especially when 
associated with conventional chemotherapy, but also offers cost-utility and cost-effectiveness advantages.
Uniterms: Non-Hodgkin’s lymphoma. Antineoplastic combined chemotherapy/protocols. Adjuvant 
chemotherapy. Rituximab/application/Non-Hodgkin’s lymphoma.
O Linfoma não-Hodgkin (LNH) consiste em um grupo de neoplasias envolvendo, principalmente, as 
células B e representa 90% de todos os linfomas. A terapia atual disponível é baseada em quimioterapia 
associada ao anticorpo monoclonal rituximabe (Mab Thera®), que tem como alvo a proteína CD20, 
presente em mais de 80% das células B maduras do LNH. Recentes relatórios clínicos mostram 
preferência para combinar os benefícios da quimioterapia adjuvante e imunoterapia, gerando alternativas 
de tratamentos seguro e eficaz. O trabalho de revisão teve por objetivo avaliar vários aspectos relacionados 
à aplicação do rituximabe no LNH, destacando os possíveis mecanismos inibitórios da proliferação 
celular, os resultados clínicos obtidos e as implicações clínicas e econômicas esperadas para o tratamento. 
Os resultados de testes clínicos indicam a necessidade de uma melhor compreensão dos mecanismos 
críticos de ação deste anticorpo, que poderão maximizar a sua eficácia terapêutica. Essa terapia não 
representa apenas uma opção viável para o tratamento da maioria dos tipos de LNH, principalmente 
quando associado à quimioterapia convencional, mas, também, oferece vantagens em termos de custo-
utilidade e custo-efetividade.
Unitermos: Linfoma não-Hodgkin. Quimioterapia combinada antineoplásica/protocolos. Quimioterapia 
adjuvante. Ribuximabe/aplicação/Linfoma não-Hodgkin.
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INTRODUCTION
Lymphomas comprise a diverse group of malignant 
neoplasias caused by clonal proliferation of B or T 
lymphocytes in lymph nodes. In general, lymphomas 
are divided into two morphologically distinct groups, 
namely Hodgkin’s Lymphoma (HL) and Non-Hodgkin’s 
Lymphoma (NHL). In particular, NHL derives from 
subpopulations of white blood cells, predominantly B 
lymphocytes (around 85%), and, generally, affects the 
central nervous system, bone marrow, peripheral lymph 
nodes, and a region near the tonsils (SBC, 2013).
NHL prevalence rates are increasing worldwide 
and are slightly higher in men, especially Caucasians. 
The average age of cases is 65, with the highest incidence 
found in people between 8085 (INCA, 2013). In Brazil, 
an estimated 9,100 new cases of the disease were reported 
in 2009, of which 4,900 were men and 4,200 women. 
Moreover, the number of deaths due to NHL in Brazil 
reached 3,568 (INCA, 2012). In the United States, the 
estimated number of new NHL cases reached 66,000 in 
2011 (National Cancer Institute, U.S., 2012). Moreover, 
some studies include NHL as the fifth cause of death by 
cancer and the main type of deadly tumor in people aged 
20 to 40 (Jazirehi, Bonavida, 2005).
Currently, over 20 types of NHL are known (INCA, 
2013), with clinical aspects varying according to histological 
type, indolent (low-grade), intermediate, or aggressive 
(high-grade) (SBC, 2013). The aggressive forms present 
a high level of cell proliferation, large cells and localized 
lymphadenopathy, and may lead to death if not treated. This 
group includes the diffuse large B cell lymphoma (DLBCL), 
representing 58% of the cases (Araújo et al., 2008).
The indolent lymphoma corresponds to 40% of 
reported cases and, although initially responsive to 
several therapies, they are characterized by a low level of 
cell proliferation, continuous and relapsing growth, low 
aggressiveness, and by being incurable. Cells are small 
and there is a formation of large masses of lymph nodes 
(INCA, 2012). Folicular lymphoma represents 70% of this 
group (Vinjamaram et al., 2011).
Distinct causes are suggested for NHL, including 
immune deficiency (e.g. Acquired Immune Deficiency 
Syndrome-AIDS), auto-immune disorders (e.g. 
Hashimoto’s thyroiditis and Sjögren Syndrome), 
infectious agents (e.g. Human T-cell Lymphotropic 
Virus type I - HTLV1, Epstein-Barr Virus-EBV and 
Helicobacter pylori), and physical and chemical agents 
(e.g. insecticides, solvents, anticonvulsants, benzenes, 
paint thinner). However, the actual etiology of most cases 
remains undetermined (SBC, 2013).
The conventional treatment for NHL generally 
involves radiotherapy and antineoplastic chemotherapy. 
Nevertheless, these options have been shown to be 
ineffective in most cases, since less than 25% of patients are 
cured (SBC, 2013) and due to the fact that chemotherapy 
is highly toxic (Chanan-Khan, 2005). The development 
and application of monoclonal antibodies (MAbs) for 
diagnosis and treatment of tumors represented a great 
advance in the management of this group of diseases. 
Among the developed MAbs, Rituximab (Mab Thera®) 
stands out, a chimeric MAb that targets the CD20 protein 
present in most part of B cells involved in NHL (Cheson, 
Leonard, 2008).
The major study that led to Rituximab’s approval 
by the U.S. Food and Drug Administration (FDA) in 1997 
showed significant activity of the drug in indolent B cell 
lymphomas, with a 50% response rate in relapsing and 
refractory disease. Furthermore, recent clinical results 
indicate its use against aggressive NHL when associated 
with conventional chemotherapies (Smith, 2003). Also 
for other types of NHL, the combination of rituximab 
with conventional chemotherapy resulted in significant 
progress in response rates, progression-free survival and 
overall survival (Kahl et al., 2010; Marcus, 2008).
Still, an improvement of rituximab-based therapies 
depends, in part, on a better understanding of the critical 
in vivo mechanisms of action, which remains unclear 
even with mechanisms such as cytotoxicity and apoptosis 
induction being suggested (Czuczman et al., 2008). 
Moreover, given the higher cost of this drug in comparison 
to conventional chemotherapies, a pharmacoeconomic 
analysis of treatments becomes necessary, as well as 
the analysis of the clinical results already achieved 
(Hernández-Rivera et al., 2008).
METHODS
The current review was performed through a 
systematic bibliographic search aimed at identifying the 
aspects relevant to the study. Medline (compiled from 
the National Library of Medicine), Bireme (International 
Database in Health Sciences), Lilacs (Latin-American 
and Caribbean Database in Health Sciences), Scielo 
Brasil and Pubmed Central® databases were used and 
several studies on the possible mechanisms of action of 
rituximab, clinical efficacy of rituximab against NHL and 
pharmacoeconomic analysis of the proposed therapies 
were selected. The terms used for the search included 
‘Rituximab’, ‘efficacy’, ‘CD20’, ‘mechanisms of action’, 
‘non-Hodgkin’s lymphoma’ and ‘pharmacoeconomics’. 
Over 40 articles were selected from these databases 
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and additional information was obtained from websites 
containing relevant information on the subject.
RESULTS AND DISCUSSION
Inhibitory mechanisms of cell proliferation
The advances obtained by genetic engineering are 
responsible for the current therapy for NHL based on 
monoclonal antibodies that act against specific markers 
expressed on tumor cells (Van Der Kolk et al., 2002). 
Among the main MAbs for clinical use, rituximab stands 
out, being a chimeric antibody predominantly human 
(95%), that targets the CD20 protein, expressed in over 80% 
of B cells of NHL and in normal B cells (Czuczman, 2002).
CD20 has been shown to be a suitable tumor 
marker, since it is found in mature normal and tumor B 
cells (Van Der Kolk et al., 2002); it is overexpressed in 
tumor B cells; it does not circulate free in plasma, which 
would inhibit antibody binding to lymphoma cells; it is 
membrane-stable; it remains attached to the cell surface 
after antibody binding and it is not internalized by the cells 
(Coiffier, 2002).
Some of the suggested inhibitory mechanisms of cell 
proliferation by rituximab are antibody-dependent cell-
mediated cytotoxicity (ADCC), complement-dependent 
cytotoxity (CDC), direct induction of apoptosis, inhibition 
of signal transduction (Cheson, Leonard, 2008) and finally 
sensitization of B cells to the cytotoxicity of chemotherapy 
drugs such as fludarabine, cisplatin, vinblastine and 
adriamycin (Jazirehi, Bonavida, 2005).
The CD20 antigen is composed of a transmembrane 
protein of 297 amino acids and its intracellular region 
is associated with tyrosine kinase. The involvement of 
this signaling molecule in several functions has been 
suggested, such as cell activation, proliferation and 
differentiation. It is believed that it also plays an important 
role in the regulation of calcium channel conductance 
and in stimulating apoptosis through the Bcl-2 protein 
(Czuczman et al., 2008; Hernández-Rivera et al., 2008).
In fact, a few researchers suggest that CD20 may 
function as a large calcium channel. One study showed that 
when CD20 was introduced in cell lines by transfection, 
there was an increase in intracellular calcium in transfected 
cells. Taking this into consideration, monoclonal 
antibodies that act against CD20, such as Rituximab, 
induce the calcium influx which leads to the release of 
caspases and induction of apoptosis, causing the death of 
tumor cells (Bishop, 2012).
NHL is also characterized by chromosomal 
translocation of Bcl-2 proto-oncogene, which occurs in 
over 80% of indolent NHL and results in the overexpression 
of the anti-apoptotic Bcl-2 protein (Czuczman, 2002). 
This protein may be involved in the lymphoma clinical 
evolution to the aggressive form, in the low survival rates 
of patients and in chemotherapy resistance. An increase 
in Bcl-2 expression in NHL results in the stabilization 
of mitochondria membrane, which prevents the release 
of cytochrome c, thus disrupting the apoptosis signaling 
cascade, responsible for the activation of caspases 
(Oliveira, Costa, Fonseca, 2006).
In order to prove this hypothesis, in vitro studies 
showed the involvement of CD20 with rituximab in 
decreasing Bcl-2 protein expression through IL-10 
inhibition and inactivation of the signal transducer and 
activator of transcription 3(STAT3). This resulted in the 
sensitization of B cells to the cytotoxic agents, allowing 
the activity of anti-tumor drugs. Thus, the activity of 
rituximab against NHL was improved when Bcl-2 was 
overexpressed in patients (Jazirehi, Bonavida, 2005).
Analysis  of  circulat ing malignant  B cel ls 
immediately after in vivo treatment with rituximab 
showed activation of caspases in these cells, which leads 
to the cleavage of several important proteins such as poly 
ADP-ribose polymerase. The apoptotic effect in malignant 
cells was observed before other potential mechanisms, 
suggesting that the direct apoptosis induced by rituximab 
may play a role in the depletion of circulating malignant B 
cells, facilitating the downstream cytotoxic effects (Byrd 
et al., 2002).
The binding mechanisms of Rituximab to CD20 
that will generate cytotoxicity are not totally known, but 
probably involve other mechanisms. ADCC involves 
the binding of the MAb Fc region to cell receptors of 
monocytes, natural killer (NK) cells and granulocytes. 
These effector immune cells cause the destruction of B 
cells bound to rituximab by phagocytosis or release of 
cytotoxic granules (Smith, 2003).
To demonstrate this mechanism, studies using 
transgenic animals that do not express receptors for antibody 
binding showed that events involving the Fc region affect 
the effectiveness of rituximab therapy. These events 
are related to ADCC modulation, which is linked to the 
presence of FcgRIII activation receptors and with the lack 
of FcgRIIB inhibitory receptors, present in myeloid cells. 
These findings also point to the importance of selecting and 
engineering therapeutic antibodies against tumors in order 
to maximize their interactions with FcgRIII and minimize 
the interactions with FcgRIIB, possibly potentiating their 
therapeutic capacities (Clynes et al., 2000).
An in vivo study showed that the absence or the 
low concentration (10 to 100 ng/mL) of fucose in the 
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oligosaccharide core of the MAb Fc region is related 
to ADCC potentiation in comparison to its fucosylated 
counterparts. This may be a promising approach for 
generating therapeutic antibodies with improved efficacy 
(Iida et al., 2009).
The association of an antibody to CD20 also initiates 
the complement cascade, resulting in the formation of 
the membrane attack complex (MAC), which will punch 
holes in the cell membrane and lead to cell lysis and 
death (Smith, 2003). Evidence for CDC was obtained 
from in vitro studies that showed rituximab activated the 
complement system to destroy a variety of lymphomas. 
However, the excitement with this discovery vanished 
when destruction of B cells induced by rituximab also 
occurred in transgenic mice deficient in complement 
factors (C1q, C3, C4). Thus, the actual role of complement 
in rituximab activity remains to be elucidated (Uchida et 
al., 2004).
The involvement of memory T cells is another 
mechanism of action that has been under focus. The 
average response period in patients that responded to 
rituximab maintenance treatment was longer than that 
observed during the first treatment with this antibody. 
This fact led some investigators to suggest that induction 
of malignant B cell death by rituximab generates apoptotic 
fragments (release of specific lymphoma antigens) that 
will be processed by antigen presenting cells (APCs, more 
specifically dendritic cells) and presented to T cells, which 
will turn into memory T cells, responsible then for the 
long-lasting response of rituximab. The activation of this 
T-cell response by or the “vaccinal effect” of rituximab 
would be responsible for an anti-lymphoma immunity 
that persists much longer than the initial cytotoxic effect 
generated by the antibody itself. Nevertheless, these 
results remain unclear and further analyses on the effect 
of these immune mechanisms are necessary to determine 
in vivo responses (Selenko et al., 2002; Rafiq, Bergtold, 
Clynes, 2002).
As noted, therapy based on the anti-CD20 antibody 
involves several other effector immune components, such 
as monocytes, macrophages, neutrophils and NK cells. 
Thus, in the case of a high tumor burden, rituximab is 
infused to saturate all accessible binding sites for CD20, 
leading to a depletion of immune effector components and, 
consequently, limiting the complete effectiveness of this 
antibody. Considering that, the association of rituximab 
with conventional anti-tumor drugs may achieve better 
results against tumors (Taylor, Lindorfer, 2008).
Another important fact is that although rituximab is 
effective in treating B cell lymphomas, 50% of affected 
people presenting relapsing low-grade lymphoma do 
not respond to the initial therapy with this drug (Belo, 
Sotomayor, 2007). Moreover, 60% of the patients that 
respond to the initial treatment are not benefited by 
maintenance treatment using only this antibody, thus 
the application of radiotherapy and antineoplastic 
chemotherapy cycles becomes necessary. It has been 
suggested that resistance to treatment arises due to 
alterations in CD20 expression or signaling, which 
increases apoptosis threshold, modulates complement 
system activity and decreases cytotoxicity (Smith, 2003).
Results on the clinical efficacy of Rituximab
Chemotherapy drugs are usually used in combinations 
such as CHOP (cyclophosphamide, doxorubicin, vincristine 
and prednisone) and CVP (cyclophosphamide, vincristine 
and prednisone). These combinations are beneficial to treat 
progressive and bulky disease and increase the response 
rates in comparison to individual drugs. However, they do 
not improve the overall survival of patients (Horváth et al., 
2009; Barr et al., 2009; Tobinai et al., 2009). Moreover, 
the use of these cocktails should be carefully evaluated in 
high-risk patients, such as those with cardiovascular and 
respiratory diseases, especially the elderly (over 60 years 
of age) (Pontes et al., 2012).
Rituximab was initially used in patients with 
relapsed follicular NHL, but later became first-line 
treatment (Foster, 2009). The main study that contributed 
to Rituximab approval by the FDA showed a significant 
activity against indolent B cell lymphomas, with a 50% 
response rate against relapsing and refractory disease using 
a weekly dose of 375 mg/m2 for four weeks. Considering the 
pharmacokinetics of MAb, the mean half-life in the plasma 
varies from 10 to 14 days, thus allowing a 375 mg/m2 
single dose per week administration schedule (Ritter et 
al., 2008). So, due to its safety and efficacy, rituximab has 
emerged as a new standard for the treatment of follicular 
NHL, alone or in association with chemotherapy (Foster, 
2009). Indeed, rituximab promotes better results when 
compared to chemotherapy alone or as a first or second line 
treatment. In combination with CVP or CHOP, Rituximab 
promotes an overall response rate of 81-97% (Vose, 2006; 
Marcus, 2008, Foster, 2009). The use of rituximab alone, 
or in combination, for patients with relapsed or refractory 
disease, results in an overall response rate (ORR) of 50-
65% (Strauss, 2006; Foster, 2009).
In the case of indolent lymphomas, an improvement 
of progression-free survival from 7 to 27 months was 
achieved (Marcus, 2007). However, better results are 
seen when rituximab is combined with antineoplastic 
chemotherapy (Belo, Sotomayor, 2007).
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A Phase II preliminary study in 40 patients, where 
31 had not been previously treated for indolent NHL, 
3 weekly cycles of CHOP were administered, with 2 
doses of rituximab at the beginning and at the end of 
this schedule, besides an infusion before the 3rd and 5th 
cycles. The overall response rate was 95% (38 out of 40 
patients), where 22 (55%) of them presented a complete 
response. The average time for disease progression was 
not achieved after 50 months of therapy and the response 
rate was 100% for patients that completed the treatment 
(Czuczman, 2002).
For the first-line treatment of follicular lymphoma, 
R-CHOP (rituximab combined with CHOP) compared 
to CHOP alone as the first-line treatment for follicular 
lymphoma, the overall response was 85.1 versus 72%, 
and the complete response rates were 29.5% and 15.6%, 
respectively. An increase in progression free survival from 
22 to 33 months was also observed (Van Oers et al., 2006).
When R-CVP (rituximab combined with CVP) 
was compared to CVP alone as the first-line treatment in 
patients with low-grade lymphoma, the overall response 
and complete remission also indicated that the combined 
chemotherapy was more advantageous, corresponding to 41 
and 81%, versus 10 and 57%, respectively (Marcus, 2007).
In addition, Chao et al. (2010) found a synergistic 
action between rituximab and the anti-CD47 antibody 
when eliminating 60% of NHL induced in mice with 
increased long-term survival. The mechanism of 
synergism involves the Fc receptor (FcR)-independent, 
enabling phagocytosis by anti-CD47 and FcR-dependent 
stimulating phagocytosis by rituximab.
Stil l  with regard to other possible therapy 
combinations, Leahy and Turner (2011) conducted a 
clinical study with 142 patients predominantly diagnosed 
with follicular NHL to assess the efficacy of iodine-131 
Rituximab radioimmunotherapy. All patients received 
the antibody with a radiation absorbed dose of 0.75 Gy, 
and reached the following results: significant overall 
response rate in 68% of patients (50% with complete 
response or unconfirmed complete response at 12 weeks); 
median overall survival of 87 months (range 1-131) and 
progression-free survival of 39 months (range 3-108). 
These results indicate a favorable response of patients to 
the iodine-131 rituximab radioimmunotherapy in routine 
clinical outpatient treatment of indolent NHL relapses, 
allowing half of the patients to achieve durable remission 
of symptoms.
Rituximab has also revolutionized treatment 
results of patients with aggressive lymphomas (including 
DLBCL) offering a higher chance of cure (76% in 5 years) 
(Belo, Sotomayor, 2007). Another study showed that 
patients with intermediate grade NHL and DLBCL were 
treated with R-CHOP. In this case, 33 patients diagnosed 
with relapsing diffuse lymphomas received 6 perfusions 
of 375 mg/m2 rituximab in the 1st day of each cycle, 
combined with 6 doses of CHOP at the 3rd day of each 
cycle. The overall response rate 94%, 20 patients (61%) 
presented complete response and 11 (33%) exhibited 
partial response. These results were further confirmed in 
a Phase III randomized trial involving 400 elderly patients 
with aggressive lymphomas, where results revealed a 
significant improvement in the overall survival when the 
combined therapy was used as opposed to CHOP alone 
(83% versus 68%) (Bishop, 2012).
The GELA study (Groupe d’Etude des linfomas 
de l’Adulte) was the first Phase III clinical trial aimed at 
evaluating the effectiveness of R-CHOP in elderly patients 
(n=399) with DLBCL. After two years, comparison of 
R-CHOP and CHOP alone showed 57% versus 38% 
survival rates free of events, 70% versus 57% overall 
survival, and 52% versus 37% complete response, 
respectively, favoring the R-CHOP therapy (Coiffier, 
2002). After 5 years, these rates remained significantly 
higher for the group with rituximab (Feugier et al., 2005).
Additionally, the influence of therapy on the 
occurrence of central nervous system (CNS) complications 
was investigated in 1,222 elderly patients (60-80 years) 
diagnosed with DLBCL and treated with CHOP with or 
without rituximab. It was found that 3.6% of the patients 
treated with R-CHOP (n=608) had CNS complications, 
whereas the frequency of such complications increased 
to 5.9% patients treated with CHOP alone (n=609). 
The estimated onset of CNS disease was 2 years, with a 
prevalence of 6.9% and 4.1% after CHOP and R-CHOP 
therapies, respectively. In conclusion, the R-CHOP 
regimen reduced the risk of CNS disorders in elderly 
patients with DLBCL (Boehme et al., 2009).
Friedberg et al. (2011) conducted a multicenter 
phase II study using the combination of rituximab/
bendamustine/bortezomib in 31 patients, of which the 
majority (74%) were men with a mean age of 64 years 
and with advanced stage disease (80% stage III/IV) and 
asymptomatic at the beginning of the study. The cycle of 
treatment lasted 28 days. Bendamustine was infused at a 
dose of 90 mg/m2 on days 1 and 4, rituximab at 375 mg/m2 
on day 1 and bortezomib at 1.3 mg/m2 on days 1, 4, 8 and 
11. All together, 30 patients received >1 cycle of therapy, 
25 patients (81%) received >4 cycles of therapy, and 29 
patients were evaluated for therapeutic response. The 
most common side effects were nausea (50%), peripheral 
neuropathy (47%), fatigue (47%), constipation (40%), 
fever (40%), and diarrhea (27%). As far as treatment, 9 
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patients showed a partial response and in 15 of them a 
complete response was recorded. Among the 19 patients 
who received 6 cycles of the therapy, 18 (95%) had a 
partial or a complete response to therapy. Despite the 
adverse effects, the study showed promising results for 
progression-free survival (PFS).
As seen, the reference treatment for DLBCL also 
indicates the use of R-CHOP, administered in 8 cycles at 
21-day intervals. Another comparative study involving 
R-CHOP versus CHOP for 7 years showed an increase 
in the overall survival (53 versus 36%, respectively). It 
is noteworthy that 7 years is longer than the minimum 
period required to consider a patient cured (5 years). 
This was observed in patients older and younger than 60 
(Hernández-Rivera et al., 2008).
The MInT (Mabthera International Trial) random 
trial investigated other chemotherapies combined with 
rituximab in patients aged between 18 and 60 and 
diagnosed with DLBCL. These patients received 6 cycles 
of conventional chemotherapies or chemotherapies 
associated with rituximab. After 34 months, the mean rates 
of event-free survival (79% versus 59%), progression-free 
survival (85% versus 66%) and overall survival (93% 
versus 84%) estimated for 3 years were higher in the 
rituximab group, with no increase in adverse events. As 
for the subgroup in stage II and with no bulky disease, 
the rate of survival, free of events, and the overall 
survival rate were 97% and 100%, respectively, in 3 
years. The worse results were seen in patients presenting 
bulky disease, where the rate of event-free survival was 
76%. Thus, the study’s conclusion was that the 6-cycle 
R-CHOP administration may be considered as the standard 
treatment for young patients with high-grade lymphoma 
(Pfreundschuh et al., 2006).
A recent study by Stopeck et al. (2012) evaluated the 
possibility of combining bevacizumab, another MAb, with 
CHOP and R-CHOP therapy to improve progression-free 
survival without adding toxicity in patients with recently 
diagnosed DLBCL and aged an average of 68. It was 
observed that 62% of patients had severe hematological 
toxicity, 11 patients had febrile neutropenia and 14 (22%) 
patients had gastrointestinal toxicity, including 5 cases 
of gastrointestinal perforation, 4 cases of thrombotic 
events and 11 developed mild ventricular dysfunction. 
Six patients older than 80 had severe toxicity (100%) 
and therefore could not complete the 8 cycles of therapy 
defined in the protocol. Based on these results, the study 
concluded that there was no benefit to the combination 
of bevacizumab and CHOP to R-CHOP, given the 
evidence of significant toxicity, particularly cardiac and 
gastrointestinal perforation.
According to Coiffier (2002), the response to 
rituximab in B cell lymphomas remained for around 2 
months, with detectable residual levels up to 6 months 
after the last infusion, indicating a long half-life of the 
antibody in circulation. During this period, normal 
B cell population declined and was recovered after 6 
months, however, there were no opportunistic infections 
or an increase in infection rates since the amount of 
antibodies and T cells remained normal. Moreover, the 
HACA (human anti-chimeric antibody) response was not 
observed and myelosupression was rare.
The most common side effects, mainly after the first 
infusion (25% of cases), are fever, chills, rigors, rash, mild 
nausea, fatigue and malaise. These effects result from the 
rapid lysis of circulating B cells during the first infusion. 
In the second infusion, since the majority of circulating 
B cells have disappeared, the adverse effects are less 
pronounced (Belo, Sotomayor, 2007). Still, the typical 
adverse effects of Rituximab do not overcome the toxic 
effects of conventional chemotherapies, justifying again 
the use of these two resources (Czuczman, 2002). These 
responses, even if partial, are important since they are 
long-lasting and point to the advantages of the combined 
therapy over the use of rituximab alone (Bishop, 2012).
Pharmacoeconomic analysis
Due to the positive results obtained by rituximab 
treatment, this drug is currently considered the preferred 
treatment for NHL. Nevertheless, there are worries over 
its costs compared to conventional treatments, since it is 
obtained through biotechnology techniques (Czuczman et 
al., 2008). In addition, therapies for costly and long-lasting 
as this type of cancer, it is necessary to the national team 
for the treatment of illness, taking into account both the 
clinical effectiveness and cost-effectiveness of treatments 
available (Foster, 2009).
According to recent data, the cost for Mab Thera® 
is over R$ 5,000 for a vial of 500 mg rituximab, and over 
R$ 3,000 for two vials of 100 mg rituximab (Anvisa, 
2013). Even information from the U.S. reports that the 
estimated cost per patient with follicular NHL is $36,000 
from diagnosis to the first year following treatment (Foster, 
2009).
Based on these data, pharmacoeconomic analyses 
were performed with rituximab through studies of cost-
utility and cost-effectiveness. Cost-utility analysis may be 
considered as a subtype of cost-effectiveness evaluation, 
where cost-efficacy considers the results in terms of 
clinical units, such as the cost per life year gained (LYG) 
and quality-adjusted life year (QALY). This is accepted as 
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cost-benefit if the incremental ratio is lower than 50,000 in 
international currencies (Yoder, Kamal, 2009).
Based on these concepts, Groot et al. (2005) 
conducted a cost-utility study involving patients with 
DLBCL assuming direct medical costs (cost of medications 
and visit two specialists per year, on average). Younger 
patients (under 60 years) have been successful in getting 
QALY R-CHOP therapy over CHOP chemotherapy alone, 
which also represented a higher cost (more than 12.343 
in total costs). Therefore, the incremental ratio for these 
patients was 13.983/QALY gains in the use of R-CHOP 
versus CHOP. A similar trend was observed with the older 
population, where the proportion was 17.933/QALY for 
incremental R-CHOP versus CHOP. Thus therapy with 
CHOP-R was found to be more cost-effective in terms 
of QALY gains while maintaining the accepted limit of 
50,000.
Ferrara and Revasio (2008) evaluated the cost-
effectiveness of R-CHOP versus CHOP in patients 
with good NHL prognosis, by analyzing responses in 3 
scenarios: patients with a complete response in 5 months 
of survival; with relapse-free survival in 3 years; and 
with overall survival in 3 years. The costs included in this 
study were those that involved CHOP and rituximab, stem 
cell transplant, apheresis with hospitalization, and those 
related with hematology and biochemical, histological 
and imaging exams. The LYG per patient was 2.697 
and 2.517 for R-CHOP and CHOP, respectively. The 
average total cost per patient was $22,113.44 for R-CHOP 
and $22,831.17 for CHOP. Thus, R-CHOP was more 
advantageous in regards to lower costs and better clinical 
results, being cost-effective when considering direct 
medical costs with good prospects in terms of LYG.
Another study evaluated the cost-effectiveness of 
maintenance treatment using the antibody in patients with 
refractory or relapsing follicular lymphoma that responded 
to R-CHOP or CHOP therapies. Through analysis of 
QALY, LYG variables and cost per year of life with no 
disease progression, the results indicated that rituximab 
was cost-effective in comparison to the standard treatment, 
since there was an increase in the progression of disease-
free survival leading to more years of life associated with a 
quality of life at an average cost of $9,358/QALY (Capote 
et al., 2008).
With regard to the R-CVP versus CVP system, a 
pharmacoeconomic analysis in patients with previously 
untreated indolent NHL was conducted in Portugal. 
Considering a time horizon of 10 years, the total cost was 
lower per patient with CVP alone (€85.838) in comparison 
with R-CVP (€87.774), with, however, an increase in life 
expectancy and QALYs per patient with an R-CVP (6.361 
and 4.166, respectively) regimen when compared to CVP 
(5.557 and 3.438, respectively), characterizing increases 
of 0.804 in LYG and 0.728 (8.7 months) in QALYs 
gained. The incremental cost per LYG was €2,407 and 
the incremental cost per QALY gained was €2,661. These 
results demonstrate that R-CVP therapy is a favorable 
alternative for indolent NHL patients, since it has shown 
positive clinical results, and cost-effectiveness (Braga et 
al. 2010).
Considering maintenance therapy with rituximab 
in follicular lymphoma, Deconinck et al. (2010) 
demonstrated the cost-effectiveness of therapy with 
respect to the number of LYGs and the total number of 
QALYs gained. 334 patients with a mean age of 54, with 
complete or partial remission, were selected to receive 
maintenance therapy with rituximab (n = 167) (375 mg/m2 
intravenously, once every three months for a maximum 
2 years) or to remain under observation without any 
additional treatment (n = 167). In the group that received 
rituximab it was observed that there was a significant 
elevation in mean PFS (51.5 months vs.14.9 months, p 
<0.001) and overall survival (OS) at 3 years (85.1% vs. 
77.1%, p = 0.011). Maintenance therapy with rituximab, 
a significant increase in both average PFS in patients who 
responded to induction with CHOP (37.5 months vs. 11.6 
months, p <0.0001) and in those who received R-CHOP 
(51, for 9 months vs. 22.1 months, p = 0.0071) was 
observed. In addition, rituximab maintenance provided 
1.19 years of additional survival time (6.60 years vs.5, 41), 
an additional 1.04 QALY (4.72 years vs. 3.68 years), and 
1.62 years most of PFS in the group of observation (3.42 
years vs. 1.80 years). The total lifetime costs were €71,314 
and €62,251 in the maintenance and observation groups, 
respectively. Therefore, maintenance with rituximab 
resulted in a gain of 1.19 years of survival or 1.04 QALYs 
at an additional cost of €9,064 compared to observation 
strategy. The relations of incremental cost-effectiveness 
were €7,612 per LYG and €8,729 per QALY. Finally, the 
results showed that the life expectancy and QALYs were 
increased by 22% and 28%, respectively.
Recently, rituximab was evaluated as a maintenance 
therapy in first-line patients with follicular NHL, 
previously responsive to rituximab associated with 
cytotoxic chemotherapy (R-CTX). The survey conducted 
by Greenhalgh et al. (2013) is based on considerations of 
the manufacturer rituximab (Roche) and the evaluation 
of a group from the University of Liverpool, hired to 
act as an Evidence Review Group (ERG). The evidence 
from randomized Phase III with 1,018 patients took into 
account parameters such as PFS, overall survival (OS), 
response rates, adverse events (Aes) treatment and quality 
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of life related to health (HR-QV). The manufacturer 
submitted an economic model (Markov) with the objective 
of demonstrating the possible benefits of maintenance 
therapy. This was accomplished in a period of two years 
to promote a projection of 25 years to capture the costs 
over the life and mean QALYs of a patient with follicular 
NHL, prospects of using the National Health Service 
(NHS, UK) and Social Service Personnel. The findings 
of this survey indicate that the data set is quite immature 
to draw definitive conclusions about the clinical and 
cost-effectiveness of the intervention. However, it was 
observed that the increase in PFS was observed in the 
primary benefit Markov model. At a third meeting, the 
Evaluation Committee concluded that rituximab could be 
recommended as the treatment of first-line maintenance 
for patients with follicular NHL whose disease has 
responded to induction with R-CTX.
CONCLUSIONS
A great advance for treating NHL patients was the 
introduction of rituximab MAb. Even though this drug 
has been used for over 10 years, its therapeutic potential 
is not totally clear. The mechanisms of cytotoxicity 
and induction of apoptosis, obtained in Phase II and III 
trials, indicate the need of further studies on the critical 
mechanisms of action involved in this treatment, which 
may maximize its therapeutic efficacy.
Results from clinical trials led rituximab Mab, 
initially approved by FDA for treating refractory or 
relapsing indolent NHL, to be included in the treatment for 
aggressive lymphomas. The association of this antibody 
to conventional chemotherapy agents such as CHOP and 
CVP has shown to be a viable option in treating almost all 
types of NHL. However, efforts continue to prospectively 
identify biological subsets of NHL needed to develop 
appropriate treatments.
The pharmacoeconomic studies cited in this review 
showed how economic analysis might influence decision-
making on future clinical efforts. LYG and QALY applied 
in these studies are applicable and frequently used in 
cancer-related research. However, in order to validate the 
obtained results, the studies need to share a broad list of the 
implicated costs (drugs, lab exams, stem cell transplant, 
medical visits, and hospitalizations). In addition, there is 
also a need to analyze the therapy over time so that, finally, 
the decision is organized and based on the real clinical 
and economic impact that it offers, since it involves the 
allocation of health resources.
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